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ANALYSIS OF VARIOUS
CAUSES OF HEMOPTYSIS
INTRODUCTION
HEMOPTYSIS
Hemoptysis is defined as the expectoration of blood derived from
the lungs or bronchial tree as a result of pulmonary or bronchial
hemorrhage. [1]
Hemoptysis is a frightening symptom for patients and often is a
manifestation of a significant underlying disease such as bronchogenic
carcinoma. [2] Expectoration of even a relatively small amount of blood
is  an  alarming  symptom,  and  massive  hemoptysis  can  be  a  life-
threatening event. Therefore, hemoptysis of any degree needs thorough
evaluation.
DIFFERENTIAL DIAGNOSIS OF HEMOPTYSIS
Source other than the lower respiratory tract
Upper  airway bleeding
Gastrointestinal bleeding
Tracheobronchial source
Neoplasm
Bronchitis (acute or chronic)
Bronchiectasis
Broncholithiasis
Airway trauma
Foreign body
Pulmonary parenchymal source
Lung abscess
Pneumonia
Tuberculosis
Mycetoma
Good pasture syndrome
Idiopathic pulmonary hemosiderosis
Wegener’s granulomatosis
Lupus pneumonitis
Lung contusion
Pulmonary vascular source
Arteriovenous malformation
Pulmonary embolism
Elevated pulmonary venous pressure (esp. mitral stenosis)
Pulmonary artery rupture secondary to balloon-tip pulmonary
artery catheter manipulation
Miscellaneous causes
     Pulmonary endometriosis (catamenial hemoptysis)
     Systemic coagulopathy or use of anticoagulants or thrombolytic
agents
Medical reviews from different parts of the world revealed that
the etiological pattern of hemoptysis has changed in the developed
countries, with pulmonary tuberculosis becoming less important as a
cause of bleeding from the lungs.  In our country, however, the pattern
has not changed. Pulmonary tuberculosis was the most common cause
of hemoptysis four decades ago as shown by Rao in his study in 1960
and it is still the leading cause of it as is evident from the present study,
in which tuberculosis was found in 72% of  patients with hemoptysis.
Various studies from other developing countries have also shown
pulmonary tuberculosis to be the major cause of hemoptysis. Studies
from developed countries have shown malignancy and non-tuberculous
causes to be the leading reasons for hemoptysis.
REVIEW OF LITERATURE
REVIEW OF LITERATURE
Hemoptysis is a nonspecific symptom and can occur in about 100
different clinical conditions. [3] In India, hemoptysis is almost
synonymous with  pulmonary tuberculosis and patients presenting with
this symptom are often  prescribed antitubercular treatment without
proper workup. The purpose of this study was to identify the various
etiologies of hemoptysis seen in our part of the country and show that
not only active pulmonary tuberculosis but also old, healed pulmonary
tuberculosis (sequelae) causes significant hemoptysis.
Differentiation between Hemoptysis and Hematemesis
HEMOPTYSIS HEMATEMESIS
HISTORY Cough Nausea/Vomiting
ASSOCIATION Sputum Food Particles
COLOUR Bright Red Dark Brown/Coffee Ground
FROTH Present Absent
REACTION Alkaline Acidic
TYPES OF HEMOPTYSIS
1. Frank Hemoptysis, in which the material coughed up consists of
wholly of blood, occurs most commonly in bronchiectasis,
pulmonary infarction, tuberculosis, mitral stenosis, and also in
bronchogenic carcinoma.
2. Blood stained sputum,  in  which  the  blood  and  sputum  are
intimately mixed up in various proportions, occurs most
commonly in bronchogenic carcinoma.
3. Blood streaked sputum, in which streaks of blood are present in
mucoid or purulent sputum, is a fairly frequent symptom in
chronic bronchitis, but may also occur in bronchogenic
carcinoma.
4. Rusty sputum in which degradation products of hemoglobin give
the sputum a colour varying between rust and golden yellow, is a
common feature of pneumococcal pneumonia and occurs in few
other conditions.
BLOOD SUPPLY OF THE LUNGS
The bronchi, the connective tissue of the lung and the visceral
pleura receive their blood supply from bronchial arteries, which are
branches of the descending aorta. The bronchial veins (which
communicate with the pulmonary veins) drain into the azygos and
hemiazygos veins.
The alveoli receive deoxygenated blood from the branches of the
pulmonary arteries. The oxygenated blood leaving the alveolar
capillaries drains into the tributaries of the pulmonary veins, which
follow the intersegmental connective tissue septa to the lung root. Two
pulmonary veins leave each lung root and empty into the left atrium of
the heart.
ETIOLOGY
The  most  common  site  of  bleeding  is  the  airway  i.e  the
tracheobronchial tree, which can be affected by inflammation (acute or
chronic bronchitis, bronchiectasis) or by neoplasm (bronchogenic
carcinoma, endobronchial metastatic carcinoma or bronchial carcinoid
tumor).
The bronchial arteries are the part of high pressure systemic
circulation, are the source of bleeding in bronchitis, bronchiectasis or
with endobronchial tumors.
Blood originating from the parenchyma can be either from a
localized source such as infection (pneumonia, lung abscess and
tuberculosis) or from a process diffusely affecting parenchyma
(coagulopathy or Good pasture’s syndrome).
Disorders primarily affecting the pulmonary vasculature include
pulmonary embolic disease and those conditions associated with
elevated pulmonary venous capillary pressure, such as mitral stenosis or
left ventricular failure.
Although the relative frequency of different etiologies of
hemoptysis varies from series to series, most recent studies indicate that
pulmonary tuberculosis is still the commonest cause of hemoptysis in
India.
Even after extensive evaluation, a sizeable proportion of patients
have no identifiable etiology for their hemoptysis. These patients are
classified as having idiopathic or cryptogenic hemoptysis and subtle
airway or parenchymal disease is presumably responsible for the
bleeding.
PULMONARY TUBERCULOSIS
Also called adult type, reactivation, or secondary tuberculosis,
post primary disease results from endogenous reactivation of latent
infection and is usually localized to the apical and posterior segments of
the upper lobes, where the substantially higher mean oxygen tension
(compared with that in the lower zones) favours mycobacterial growth.
In addition, the superior segments of the lower lobes are frequently
involved. The extent of lung parenchymal involvement varies greatly,
from small infiltrates to extensive cavitatory disease. With cavity
formation, liquified necrotic contents are ultimately discharged into the
airways, resulting in satellite lesions within the lungs that may inturn
undergo cavitation. Massive involvement of pulmonary segments or
lobes, with coalescence of lesions, produces tuberculous pneumonia.
While up to one third of untreated patients reportedly succumb to severe
pulmonary tuberculosis within a few weeks or months after onset
(the classical galloping consumption of the past). Others undergo a
process of spontaneous remission or proceed along a chronic,
progressively debilitating course. Under these circumstances, some
pulmonary lesions become fibrotic and may later calcify, but cavities
persist  in other parts of the lungs. Individuals with such chronic disease
continue to discharge tubercle bacilli into the environment. Most
patients respond to treatment, with defervescence, decreasing cough,
weight gain, and a general improvement in well being within several
weeks.
Early in the course of disease, symptoms and signs are often non-
specific and insidious, consisting mainly of fever and night sweats,
weight loss, anorexia, general malaise, and weakness. However, in the
majority of cases, cough eventually develops- often initially
nonproductive and subsequently accompanied by the production of
purulent sputum, sometimes with blood streaking. Massive hemoptysis
may ensue as a consequence of  the erosion of a blood vessel in the wall
of  a  cavity.  Hemoptysis,  however,  may  also  result  from  rupture  of  a
dilated vessel in an old cavity (Rasmussen’s aneurysm) or from
aspergilloma formation  in an old cavity.
Pleuritic chest pain sometimes develops in patients with
subpleural parenchymal lesions. Extensive disease may produce
dyspnoea and, in rare instances, adult respiratory distress syndrome.
Physical findings are of limited use in pulmonary tuberculosis. Many
patients have no abnormalities detectable by chest examination, whereas
others have detectable rales in the involved areas during inspiration,
especially after coughing. Occasionally, rhonchi due to partial bronchial
obstruction and classic amphoric breath sounds in areas with large
cavities may be heard. Systemic features include fever (often low grade
and intermittent) in up to 80% of cases and wasting. Absence of fever,
however, does not exclude tuberculosis. In some cases, pallor and finger
clubbing develop. The most common hematologic findings are mild
anemia and leukocytosis. Hyponatremia due to the syndrome of
inappropriate secretion of antidiuretic hormone (SIADH) has also been
reported.
BRONCHITIS
Chronic Bronchitis is associated with chronic cough and phlegm.
Risk factor being cigarette smoking, airway responsiveness, repeated
respiratory tract infections, occupational exposure to coal mining, gold
mining and cotton textile dust, air pollution and passive smoking.
Persistent reduction in expiratory flow rates is the most typical finding
in  COPD.  Patients  with  airflow  obstruction  related  to  COPD  have  a
chronically reduced ratio of  FEV1/FVC. Cigarette smoke exposure may
affect the large airways, small airway(<2mm in diameter) and alveolar
space. Cigarette smoking often results in mucous gland enlargement and
goblet cell hyperplasia. Patients with chronic bronchitis may have
smooth muscle hyperplasia and bronchial hyper reactivity leading to
airflow limitation. Three most common symptoms in COPD are cough,
sputum production and exertional dyspnoea.
Patients with chronic bronchitis are quite frequently cigarette
smokers and hemoptysis in these patients attributed to bronchitis
without careful exclusion of neoplasm as a potential cause of bleeding.
The hemoptysis in chronic bronchitis is most often blood streaking of
sputum. Massive bleeding is unusual. In acute bronchitis, bleeding
results from irritation of the unusually friable and vascular mucosa.
BRONCHIECTASIS
Bronchiectasis has been a common cause of hemoptysis.
Bronchiectatic lungs show significant enlargement of the bronchial
arteries as well as numerous and large anastamoses of the bronchial
arteries with pulmonary arteries. The enlargement of the bronchial
vessels is associated with the development granulation tissue and
destructive rearrangement of the bronchial wall. Hemoptysis can be
slight or massive and is often recurrent. Unusually associated with
purulent sputum or an increase in sputum purulence. Hemoptysis can,
however, be the only symptom in so called dry bronchiectasis.
PNEUMONIA
Pneumonia is one of the causes of hemoptysis. The classic
presentation of pneumonia is cough with fever with variable amount of
sputum production, hemoptysis, dyspnoea and pleurisy.
In pneumococcal pneumonia the sputum is productive with blood
streaked or rusty sputum. In pneumonia due to anaerobic bacteria,
sputum is often purulent.
LUNG ABSCESS
Both acute and chronic lung abscess have a propensity for
hemoptysis.  After  one  to  two  weeks  of  infection,  tissue  necrosis  with
abscess formation or empyema occurs. Following cavitation, putrid
sputum is noted in 50% or more of patients and hemoptysis may be
seen.
In a large group of hemoptysis patients, lung abscess was
responsible in approximately 5%. Bleeding may arise either from
granulation tissues lining the abscess cavity or from a small branch of
pulmonary  or  bronchial   arteries.  A  small  frank  hemoptysis  may  often
precede the rupture of an abscess and the abscess contents are grossly
blood stained during the first few days of rupture.
Certain radiologic signs described by Thomas are useful in
identifying actual or impending hemoptysis.
1. Emptying and refilling of the abscess cavity on serial films.
2. Variations in the lucency and height of the air fluid level.
3. Variable parenchymal densities representing blood clots within
the cavity.
In fungal infections also hemoptysis can occur. Pulmonary
blastomycosis occurs in immuno compromised hosts. Within weeks to
months, suppurative necrosis results in sputum production, which may
be purulent and blood tinged. Endobronchial saprophytic pulmonary
aspergillosis presents as chronic productive cough often with
hemoptysis.
MITRAL STENOSIS
In mitral stenosis hemoptysis may result from a variety of causes.
It is usually due to increased pulmonary venous pressure, pink frothy
sputum may result from rupture of alveolar capillaries associated with
acute pulmonary edema or from pulmonary infarction due to pulmonary
embolism. Hemoptysis may be severe and profuse(pulmonary
apoplexy). The edematous bronchial mucosa is more likely to be
associated with chronic bronchitis resulting  in blood stained sputum.
ANTICOAGULATION THERAPY
Long term anticoagulation therapy is associated with bleeding
episodes. The incidence of minor bleeding is less than 2 to 3% per year.
The incidence of major bleeding is 4 to 11% per year depending upon
patient’s age and associated comorbid conditions. The incidence of these
complications is lower in those who receive low dose warfarin
therapy(INR 2 to 3 vs >3).
The overall improvement in the anticoagulation control in the past
10 to 15 years has reduced the incidence of bleeding in these patients  to
about 0.2%. Review of observational and experimental studies showed
annual bleeding rates of 0 to 4.8% for fatal bleeding and 2.4 to 8.1% for
major bleeding. Age is the main factor that increases the risk of
bleeding.
Pulmonary hemorrhage is the most serious type of bleeding and
varies from mild and occasional copious, recurrent, massive and fatal
bleeding. Massive intrapulmonary hemorrhage is a common cause of
death in Eissenmenger syndrome. Hemoptysis occurs most often in the
presence of  pulmonary vascular obstructive disease or in patients with
extensive bronchial collateral circulation or pulmonary venous
congestion.
PULMONARY THROMBO EMBOLISM
Dyspnoea is the most frequent symptom of pulmonary embolism
and tachypnoea is its most frequent sign. Dyspnoea, syncope,
hypotension or cyanosis indicates a massive pulmonary embolism.
Pleuritic pain, cough or hemoptysis often suggests a small embolism
located distally near the pleura.
             Classic abnormalities in ECG include sinus tachycardia, new
onset atrial fibrillation or flutter, and an S wave in lead I, a Q wave in
lead III. Often the QRS axis is greater than 90. A normal or near normal
chest  Xray  in  a  dyspnoeic  patient  suggests  pulmonary  embolism.
Abnormalities may be  focal oligemia (Westermack’s sign), a peripheral
wedge shaped density above the diaphragm (Hampton’s hump) or an
enlarged right descending pulmonary artery ( Palla sign). Computed
tomography of the chest is the investigation of choice.
BRONCHIAL CARCINOID
              Bronchial carcinoid is a rare tumor that resembles intestinal
carcinoid tumor and is locally invasive eventually spreading to
mediastinal lymph nodes and finally to distant organs.  It is a highly
vascular tumor that projects in to the lumen of a major bronchus causing
recurrent hemoptysis.
BRONCHIAL ADENOMA
              Bronchial adenoma are slowly growing, endobronchial lesions.
Adenomas present in patients aged 15 to 60 years. Patients may have
chronic cough, recurrent hemoptysis or obstruction with atelectasis.
BRONCHOGENIC CARCINOMA
 Bronchogenic carcinoma is one of the common causes of
hemoptysis especially in old age males. In squamous cell carcinoma
hemoptysis may be minimal i.e., minimal streaking of blood in mucoid
sputum. Copious hemoptysis is uncommon. Squamous cell carcinomas
are usually centrally located tumors. It  usually occurs in smokers.
             Adenocarcinomas are common in non smoking individuals and
in female patients. Adenocarcinomas are usually peripherally located
tumors, cough and hemoptysis are less common in peripheral
neoplasms.
CHEST INJURIES
Hemoptysis follows a variety of chest injuries. Puncture of a lung
by a fractured rib, contusion of a lung by severe blunt trauma to the
chest and necrosis of the lining of the tracheo bronchial tree by inhaled
fumes  or  smoke.  Blunt  trauma  from  the  steering  wheel  during  an
automobile collision sometimes lacerates or fractures the tracheo
bronchial tree. Stab or gunshot wounds often tear the lungs or airways
resulting in hemoptysis.
BLEEDING DISORDERS
In hemophiliacs, pulmonary and pleural bleeding are uncommon,
although mediastinal and pleural shadows have been noted
radiographically and presumably originate from fresh or old hematomas.
Patients with <1% factor 8 activity have severe disease. Patients with
levels 1 to 3% have moderate disease. Those with levels >8% have mild
disease. Typically patients present with pain followed by swelling in a
weight bearing joint, usually knee(hemarthrosis) leading to joint
ankylosis. The most feared complications of hemophilia are
oropharyngeal and central nervous system bleeding.
GOOD PASTURE’S SYNDROME
Good pasture syndrome is an auto immune disease in which auto
antibodies are directed against type IV collagen. In 50% to 70% of
patients have lung hemorrhage. Other features are hematuria, nephritic
urinary sediment and sub nephrotic proteinuria.
WEGENER’S GRANULOMATOSIS
In wegener’s granulomatosis, pulmonary involvement may be
manifested as asymptomatic infiltrates or may be clinically expressed as
cough, hemoptysis, dyspnea and chest discomfort. It is present in 85 to
90%  of patients. In its classical form it presents as a characteristic triad
of ELK i.e upper airway(ENT), lung(L) and renal disease(K-Kidney).
It is characterised by necrotising granulomatous inflammation in the
vessels in the ENT area and the lower respiratory tract.
SYSTEMIC LUPUS ERYTHEMATOSUS
In systemic lupus erythematosus most common manifestations is
pleuritis with or without pleural effusion. Life threatening
manifestations include interstitial inflammation leading to fibrosis and
intraalveolar hemorrhage.
Lupus pneumonitis and diffuse infiltrative lung disease or
interstitial lung disease can occur. Pulmonary hemorrhage is a rare but
serious manifestation.
SNAKE BITE
Bleeding and clotting disturbances are seen after bites by vipers,
pit vipers, Australian elapids and dangerously venomous colubrids.
Snake venoms can cause hemostatic defects in a number of ways.
Venom procoagulants can activate intravascular coagulation and
produce consumption coagulopathy leading to incoagulable blood. For
example,  procoagulants in the venom of colubrids activate prothrombin
and many crotalinae venoms have a direct thrombin like action on
fibrinogen. Anticoagulant activity is attributable to venom
phospholipases. Thrombocytopenia is a common accompaniment of
systemic envenomations.
In patients bitten by Malayan pit vipers and green pit vipers there
is initially inhibition of platelet aggregation followed by activation and
the appearance of circulating clumps of platelets. Spontaneous systemic
bleeding attributable to distinct venom components, hemorrhagins,
which damage vascular endothelium. The combination of incoagulable
blood, thrombocytopenia and vessel wall damage will result in massive
bleeding, a common cause of death from viper bites.
BLEEDING MANIFESTATION IN CHRONIC KIDNEY
DISEASE
The etiology is multifactorial and that the defect mainly involves
primary hemostasis. The impairement of primary hemostasis in uremia
has two constant abnormalities, reduced adhesiveness of platelets and
prolonged bleeding time. A direct correlation has been found between
the prolonged bleeding time and clinical bleeding in uremic patients.
Antithrombin III is increased, while protein C anticoagulant
activity is decreased, due to an inhibitor that interferes with
anticoagulant properties of  activated protein C. Though the platelet
count is within the normal range, complex abnormalities in platelet
functions have been noted. They include reduction in adenosine
diphosphate and serotonin content, a defect in the mechanisms of
platelet secretion and release of alpha granule protein and beta
thromboglobulin, increased platelet cyclic adenosine monophosphate
and reduced generation of thromboxane A-2. Platelets from uremic
patients have an impaired glycoprotein 2b-3a complex receptor function.
Emerging evidence is also available that the bleeding tendency in
uremia is related to an excessive formation of nitric oxide, an unstable,
potent vasoactive molecule which also inhibits platelet function.
Hematological dysfunction may be an untoward side effect of
drug treatment, and uremic patients are at an increased risk of bleeding
of complications caused by drug therapy especially after administration
of beta lactam antibiotics.
DIAGNOSING NON MASSIVE HEMOPTYSIS
DIAGNOSTIC CLUES IN HEMOPTYSIS:
PHYSICAL HISTORY
Clinical clues Suggested diagnosis*
Anticoagulant use Medication
effect
Coagulation disorder
Association with menses Catamenial hemoptysis
Dyspnea on exertion, fatigue,
orthopnea, paroxysmal nocturnal
dyspnea, frothy pink sputum
Congestive heart failure,    mitral
valve stenosis left ventricular
dysfunction,
Fever, productive cough Upper respiratory infection, acute
sinusitis,  acute bronchitis,
pneumonia, lung abscess
History of breast, colon, or renal
cancers
Endobronchial metastatic disease of
lungs
History of chronic lung disease,
recurrent lower respiratory track
infection, cough with copious
purulent sputum
Bronchiectasis, lung abscess
HIV, immunosuppression Neoplasia, tuberculosis, Kaposi’s
sarcoma
Nausea, vomiting, melena,
alcoholism, chronic use of
nonsteroidal anti-inflammatory
drugs
Gastritis, gastric or peptic ulcer,
esophageal varices
Pleuritic chest pain, calf
tenderness
Pulmonary embolism or infarction
Tobacco use Acute bronchitis, chronic bronchitis,
lung cancer, pneumonia.
Travel history Tuberculosis, parasites (e.g.,
paragonimiasis, schistosomiasis,
amebiasis, leptospirosis), biologic
agents  (e.g.,  plague,  tularemia,  T2
mycotoxin).
Weight loss Emphysema, lung cancer,
tuberculosis, bronchiectasis, lung
abscess, HIV.
HIV = human immunodeficiency virus.
PHYSICAL EXAMINATION
Clinical clues Suggested diagnosis*
Cachexia, clubbing, voice
hoarseness, Cushing’s
syndrome, hyperpigmentation,
Horner’s syndrome
Bronchogenic carcinoma, small cell
lung cancer, other primary lung
cancers
Clubbing Primary lung cancer, bronchiectasis,
lung abscess, severe chronic lung
disease, secondary lung metastases
Dullness to percussion, fever,
unilateral rales
Pneumonia
Facial tenderness, fever,
mucopurulent nasal discharge,
postnasal drainage
Acute upper respiratory infection,
acute sinusitis
Fever, tachypnea, hypoxia,
hypertrophied accessory
respiratory muscles, barrel chest,
intercostal retractions, pursed lip
breathing, rhonchi, wheezing,
tympani to percussion, distant
heart sounds
Acute exacerbation of chronic
bronchitis, primary lung cancer,
pneumonia
Gingival thickening, mulberry
gingivitis, saddle nose, nasal
septum perforation
Wegener’s granulomatosis
Heart murmur, pectus
excavatum
Mitral valve stenosis
Lymph node enlargement,
cachexia, violaceous tumors on
skin
Kaposi’s sarcoma secondary to
human immunodeficiency virus
infection
Orofacial and mucous
membrane telangiectasia,
epistaxis
Osler-Weber-Rendu disease
Tachycardia, tachypnea,
hypoxia, jugulovenous
distention, S3 gallop, decreased
lung sounds, bilateral rales,
dullness to percussion in lower
lung fields
Congestive heart failure caused by
left ventricular dysfunction or severe
mitral valve stenosis
Tachypnea, tachycardia,
dyspnea, fixed split S2, pleural
friction rub, unilateral leg pain
and edema
Pulmonary thromboembolic disease
Tympani to percussion over lung
apices, cachexia
Tuberculosis
Laboratory Tests Diagnostic findings
White blood cell count and
differential count.
Elevated cell count and differential
shifts may be present in upper and
lower respiratory tract infections
Hemoglobin, hematocrit Decreased in anemia
Platelet count Decreased in thrombocytopenia
Prothrombin time, International
Normalized Ratio, partial
thromboplastin time
Increased in anticoagulant use,
disorders of coagulation
Arterial blood gases Hypoxia, hypercarbia
D-dimer Elevated in pulmonary embolism
Sputum Gram stain, culture,
acid-fast bacillus smear and
culture
Pneumonia, lung abscess,
tuberculosis, mycobacterial
infections
Sputum cytology Neoplasm
Purified protein derivative skin
test
Positive - increases risk for
tuberculosis
Human immunodeficiency virus
test
Positive - increases risk for
tuberculosis, Kaposi’s sarcoma
Erythrocyte sedimentation rate  Elevated in infection, autoimmune
disorders (e.g., Wegener’s
Granulomatosis, systemic lupus
erythematosus, sarcoid,
Goodpasture’s syndrome), may be
elevated in neoplasia
Chest radiograph finding Suggested diagnosis*
Cardiomegaly, increased
pulmonary vascular distribution
Chronic heart failure, mitral valve
stenosis
Cavitary lesions Lung abscess, tuberculosis,
necrotizing carcinoma
Diffuse alveolar infiltrates  Chronic heart failure, pulmonary
edema, aspiration, toxic injury
Hilar adenopathy or mass Carcinoma, metastatic disease,
infectious process, sarcoid
Hyperinflation Chronic obstructive pulmonary
disease
Lobar or segmental infiltrates  Pneumonia, thromboembolism,
obstructing carcinoma
Mass lesion, nodules,
granulomas
Carcinoma, metastatic disease,
Wegener’s granulomatosis, septic
embolism, vasculitides
Normal or no change from
baseline
Bronchitis, upper respiratory
infection, sinusitis, pulmonary
embolism
Patchy alveolar infiltrates
(multiple bleeding sites)
Bleeding disorders, idiopathic
pulmonary hemosiderosis,
Goodpasture’s syndrome
OBJECTIVE
OBJECTIVE
1. To analyse the various etiological factors of hemoptysis prevalent
in  our part of the country.
2. To show that not only pulmonary tuberculosis but also its
sequelae is a major cause of hemoptysis .
MATERIALS AND
METHODS
MATERIALS AND METHODS
                     Hundred  consecutive  patients  of  hemoptysis  who  were
admitted  to  the  medical  wards  of  the  Institute  of  Internal
Medicine, Government  General  Hospital,  Chennai were  included  in
this  study.
Type of study:    Cross sectional study
Duration of study:    May  2010 - October 2010
Statistical Analysis : SPSS Software
Inclusion criteria:
1. Inpatients  of  medical  wards  in  GGH,  Chennai-  3  with
symptoms of hemoptysis
2. Age more than 14 years.
3. Both males and females are included in this study
Exclusion criteria:
1. Patients who have been embolised earlier and presenting
with   hemoptysis again.
2. Age less than 14 years
Approval  from  the  institute's  ethical  committee  and  informed
consent  from  all  patients  was  obtained  prior  to  commencement  of
the study.  Demographic  data,  including  sex  and  age,  was  collected.
The  amount   of   hemoptysis   was   also   noted.   Every   patient   was
asked  to  collect the  expectorated  blood  in  a  glass.  The  amount  of
hemoptysis   was  recorded   and   converted   to   a   milliliter   equivalent
 ( i.e.,  one  small  glass = 100 ml ).  The  episodes  of  hemoptysis  were
stratified   into   three   groups  according   to   the   amount   of   blood
expectorated, i.e.,  mild:  < 100 ml/day; moderate:  100-300 ml/day;
massive:  >300 ml/day.
Patients  were  also  grouped  into  categories  on  the  basis  of
their   primary   diagnosis  (  like   pulmonary   tuberculosis,   neoplasm,
chronic  bronchitis,  bronchiectasis,  others,  etc).  Diagnosis  was  made
after  thorough  clinical  evaluation  and  appropriate  investigations  like
chest  radiography, echocardiogram, sputum examination, computed
tomography  of  thorax (CT), bronchoscopy, CT guided biopsy.
Diagnosis   of   pulmonary   tuberculosis   was   based   on   chest
radiography  and  sputum  examination  for  acid  fast  bacilli.  A  chest
radiograph  demonstrating  nodular,  alveolar,  or  interstitial  infiltrates
predominantly   affecting   the   upper   zone   of   the   lung(s)   in
symptomatic  patients ( i.e.,  those  with  cough,  weight loss,  and  fever
with  night  sweat) were  considered  suggestive  of  active  pulmonary
tuberculosis.  When  the  chest  radiograph  showed  inactive  processes
such  as  calcified  granuloma,  and  there  were  no  symptoms  other
than   hemoptysis,   the   patient   was  diagnosed   as   having   inactive
pulmonary  tuberculosis.  For  bronchogenic carcinoma,  diagnosis  was
based  on  histopathology.  Bronchitis  was diagnosed  when  a  patient
had  symptoms  consistent  with  upper  airway infection  and  a  normal
chest   radiograph.   Diagnosis   of   bronchiectasis   was  confirmed   by
high-resolution  CT  of  thorax.
Hemoptysis  was  categorized  as
1. Mild (< 100 ml/day)
2. Moderate (100-300 ml/day)
      3. Massive (>300 ml/day).
We also categorized the patients according to the primary etiology
of the hemoptysis.
RESULTS
OBSERVATION AND RESULTS
VARIOUS CAUSES OF HEMOPTYSIS
Diagnosis No. of patients
 Pulmonary tuberculosis 52
    PT sequelae 21
    Malignancy 7
    Bronchiectasis 6
    Chronic bronchitis 5
    Rheumatic heart disease 4
    Lung abscess 2
    Pneumonia 2
    Aspergilloma 1
Sex No. of patients
Male 50
Female 50
             Of the 100 patients with hemoptysis included in this study, 50
were males and 50 were females. Pulmonary tuberculosis was the
leading cause of hemoptysis. There were 73 patients in the pulmonary
tuberculosis group (includes both active and inactive), 7 in the neoplasm
group, 5 in the chronic bronchitis group, 6 in the bronchiectasis group, 4
were due to rheumatic heart disease, 2 were due to lung abscess and 2
were due to pneumonia and 1 due to aspergilloma.
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From the above representation, we see that PT sequelae, chronic
bronchitis and bronchiectasis seem to be more in males. All other
conditions are almost equally distributed in both sexes.
Common causes of Hemoptysis
From the above bar diagram we see that active pulmonary
tuberculosis is the major cause of hemoptysis contributing 50%, i.e.,
every second case of hemoptysis is due to PT. Also PT sequelae
(inactive PT) ranks second in the list contributing about 21% of the
cases. Other causes like bronchitis, malignancy which make up the huge
chunk of cases in the western world are only a minor cause of hemoptyis
in our country.
Statistical Analysis
Observed N Expected N Residual
PT 52 11.1 40.9
PT Seq 21 11.1 9.9
Chr Br 5 11.1 -6.1
Ca Br 7 11.1 -4.1
BE 6 11.1 -5.1
RHD 4 11.1 -7.1
LA 2 11.1 -9.1
Pneum 2 11.1 -9.1
Asper 1 11.1 -10.1
Total 100
p value is <0.001. It  is significant at  1% level.
PIE CHART SHOWING CAUSES OF HEMOPTYSIS
CONCLUSION
CONCLUSION
1. Although pulmonary tuberculosis is the most important cause of
hemoptysis in India, it may also occur due to a variety of other
causes. Antitubercular treatment should not be started without
proper diagnostic workup.
2.  The fact that all who have hemoptysis do not have tuberculosis and
all tuberculosis patients don’t present  hemoptysis should be kept in
mind, always.
3. Another point of interest is that patients with hemoptysis need not
always have active tuberculosis. About 20% of patients had
hemoptysis due to PT sequelae/ inactive tuberculosis.
4. In our country, pulmonary tuberculosis and its sequelae, continues to
be the predominant cause contributing to about 73% of cases of
hemoptysis whereas malignancy and bronchitis seems to
predominate the etiology list only in developed countries.
BRONCHIAL ARTERY
EMBOLISATION
BRONCHIAL ARTERY EMBOLISATION
Life-threatening hemoptysis is one of the most challenging
conditions encountered in critical care and requires a thorough and
timely investigation. Despite advances in medical and intensive care unit
management, massive hemoptysis remains a serious threat. According to
recently published data, 28% of chest clinicians had experienced a
patient’s death from massive hemoptysis during a previous 1-year
period (6). Conservative management of massive hemoptysis carries a
mortality rate of 50%–100% (7). The cause of death is usually
asphyxiation, not exsanguination (8). The reported mortality rates for
surgery performed for massive hemoptysis range from 7.1% to 18.2%
(9). However, the mortality rate increases significantly, up to about
40%, when the surgery is undertaken as an emergency procedure (10).
Bronchial artery embolization (BAE) has become an established
procedure in the management of massive and recurrent hemoptysis; its
use was first reported in 1973 by Remy et al (11). The efficacy, safety,
and utility of BAE in controlling massive hemoptysis have been well
documented in many subsequent reports (11-19). Because of poor
pulmonary reserve and other medical comorbid conditions, most
patients with massive hemoptysis are not surgical candidates (7,8).
However, surgery remains the procedure of choice in the treatment of
massive hemoptysis caused by specific conditions, such as hydatid cyst,
thoracic vascular injury, bronchial adenoma, and aspergilloma that is
resistant to other therapies (20). Even in surgical candidates, BAE is
effective in preparing the patient for elective rather than high-risk
emergency surgery (9).
AIM OF THE STUDY
AIM OF THE STUDY
To determine the success rate of Bronchial Artery Embolisation,
performed for patients of massive hemoptysis (due to pulmonary
tuberculosis or its sequalae), during the first six months follow up
period.
REVIEW OF LITERATURE
REVIEW OF LITERATURE
The source of massive hemoptysis is usually the bronchial
circulation (90% of cases) rather than the pulmonary circulation (5%)
(23). In a minority of cases (5%), massive hemoptysis may originate
within the aorta (eg, aortobronchial fistula, ruptured aortic aneurysm) or
the systemic arterial supply to the lungs (24–26). In many acute and
chronic lung diseases, pulmonary circulation is reduced or occluded at
the level of the pulmonary arterioles because of hypoxic
vasoconstriction, intravascular thrombosis, and vasculitis (27). As a
result, bronchial arteries proliferate and enlarge to replace the
pulmonary circulation. The enlarged bronchial vessels, which exist in an
area of active or chronic inflammation, may be ruptured due to erosion
by a bacterial agent or due to elevated regional blood pressure. The
arterial blood under systemic arterial pressure subsequently extravasates
into the respiratory tree, resulting in massive hemoptysis (27,28).
Bronchial artery embolization is mainly performed for control of life-
threatening massive haemoptysis (expectoration of blood). It can also be
performed for patients with recurrent episodes of small volume
hemoptysis, who are not fit for surgery,  although 20% of these patients
will rebleed within next 6 months.
The long-term success rate is 45% to 58%. Immediate control of
haemorrhage is achieved in 75% to 95% of patients.
MATERIALS AND
METHODS
MATERIALS AND METHODS
Type of study:  Follow up study
Duration of study: May 2010 to October 2010
Statistical Analysis :  SPSS Software
Inclusion criteria
1. All tuberculosis patients who have been admitted in the
medical  wards  of  GGH,  Chennai-  3  for  complaints  of
hemoptysis.
2. Both active and inactive tuberculosis patients are included in
this study.
3. Hemodynamically stable patients.
4. Aged above 14years.
Exclusion criteria
1. Hemoptysis not of TB origin.
2.  Patients who have been embolised earlier for similar
complaints.
Twenty patients between the ages of 16 and 65 years, with a mean
age of 40.5 years formed the group. There were 15 men and 05 women.
All the patients had massive hemoptysis and were been treated for
tuberculosis in the past/present. The criteria for massive hemoptysis
were:
More than 300 ml of blood in 24 hours.
More than 100 ml per day for more than 2 days.
Procedure
• Before the procedure, chest X-ray, computed tomography (CT) and
bronchoscopy was performed to locate the bleeding site.
• Under X-ray fluoroscopic guidance, angiography with digital
subtraction facility was performed for delineation of vascular structures.
The arterial access was usually via the common femoral artery at the
groin region. Approach via brachial artery or radial artery at the upper
limb was occasionally needed.
• The bronchial artery and the other arteries supplying the bleeding sites
was  identified and selectively cannulated with catheter. A smaller co-
axial catheter through the original catheter was commonly used for
superselective catheterization. The spinal artery was avoided or
bypassed if it was  identified.
• Particles were then injected through the catheter to block the arteries.
Gel foam was used.
• The procedure usually required 2-4 hours.
• After the procedure, vital signs (e.g., blood pressure and pulse rate)
were  monitored Cavitatory and non-cavitatory lesions were seen in 12
and 8 patients respectively. Patients were followed up for two days as
in-patients and thereafter for six months as outpatients.
Potential Complications
With the use of non-ionic contrast medium, coaxial catheters and
digital subtraction angiographic technique, serious complications arising
from bronchial artery embolization is not common.
• Particles flowing to the spinal artery, causing spinal artery occlusion
and resulting in paralysis of the legs and lower part of the body – very
rare.
• Injury of bronchial artery with life-threatening bleeding – rare.
• Non-target embolization of branches of subclavian artery causing
injury to other organs: brainstem, fingers – rare.
• Chest pain and difficulty in swallowing: These may occur 2-7 days
after embolization and are usually self-limiting.
• Vascular damage due to arterial puncture or manipulation of guidewire
and catheter: rare.
• Transverse myelitis (inflammation of the spinal cord): rare.
• Fistula formation between the bronchus and esophagus: rare.
• Death of bronchial tissue: rare.
• Procedure related death is rare.
• The overall adverse reactions related to iodine-base contrast medium is
below 0.7%.
The mortality due to reaction to non-ionic contrast medium is
below 1 in 250000.
RESULTS
OBSERVATION AND RESULTS
Control of bleeding No of patients
Immediate control 14
Recurrence within 24 hrs 1
Recurrence > 24 hours 4
Therapeutic embolization was achieved in 19 patients. In one, the
required artery could not be catheterized. Dilated, tortuous bronchial
arteries were seen at the site of lesion. Patients with bronchial to
pulmonary artery shunting were also embolised. The average time taken
for the procedure was forty-five minutes.
In one patient, spinal arteries were found to originate from a
major bronchial artery. In this case, the catheter  was  negotiated beyond
the origin of the spinal arteries.
The criterion for successful embolization was expectoration of
less than 100 ml of blood in the 24 hours following the procedure.
Occasional blood stained sputum was seen up to one week
following the procedure and cessation of this was considered success.
imm control
74%
rec<24hrs
5%
rec>24hrs
21%
BAE results
imm
control
rec<24hrs
Hemoptysis of more than 100ml in twenty-four hours was considered as
treatment failure.
These patients were followed up for a period of six months. They
were instructed well to contact us in case of any recurrence of symptoms
and to get hospitalized at the earliest. Of the 19 patients who underwent
BAE procedure, 14 of them stayed asymptomatic throughout the six
month follow up period, 1 developed hemoptysis within 24 hours of the
procedure and 4 experienced hemoptysis during the six month follow up
period.
Post procedural hemoptysis
Observed N Expected N Residual
Present 5 9.5 -4.5
Absent 14 9.5 4.5
Total 19
p value is 0.039.  It is significant at 5% level.
DISCUSSION
Most of the patients with massive hemoptysis are poor surgical
candidates as they lack respiratory reserve [32]. Bronchial artery
embolization provides effective management in patients, when massive
hemoptysis results from the sequelae of tuberculosis rather than
complications of the disease [33],[34]. The bronchial arteries are the
most common source of massive hemoptysis in these patients.
This is usually due to chronic bronchial inflammation leading to
bronchial artery hypertrophy and an aneurysmal dilatation of these
vessels [35], [36].
On angiography, the major source of hemorrhage is the bronchial
vessel and hypervascularity is the single most common pathological
abnormality on the affected side [37],[38]. Generally, cavities are the
source of hemoptysis and the arteries supplying these cavities were
always  embolised  [39].  The  presence  of  the  anterior  spinal  artery  as  a
branch of the costocervical trunk was not considered to be a
contraindication for the procedure [40].
According to our study, BAE success rate is 74%.
CONCLUSION
CONCLUSION
1. To conclude, bronchial artery embolization is a safe and simple
procedure not associated with any significant complication.
2. The  success  rate  of  BAE  is  about  74%  for  the  first  six  month
follow up period as per our study.
3. BAE  clearly reduces the mortality rate in hemoptysis and hence
can be done for all cases provided the facility and trained
personnel are available.
4. According  to our study  cavitatory lesions  were found to be the
common source of  bleed in hemoptysis patients.
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STUDY PROFORMA
Name :
Age/Sex :
Address :
Annual Income :
Socio Economic Class :
MRD No. :
Study Id No. :
Clinical  Data :
History :
Presenting Complaints  :
Cough / Expectoration / chest pain /  fever /  loss of appetite / loss of
weight / Hemoptysis / breathlessness / foul  smelling sputum / blood
stained sputum.
Past History :
Diabetes Mellitus / Systemic hypertension / Cardiac disease / PT /
Bleeding  Diathesis
Treatment history :
Personal history :
Smoking / Alcohol / menstrual  complaints for female patients.
PHYSICAL EXAMINATION :
General examination / General well being / dyspnoea / pallor /
jaundice / pedal edema  / Lymphadenopathy / Clubbing.
Vital Signs :
Pulse  rate : BP :
Respiratory rate : Temp :
JVP :
Systemic Examination  :
CVS :
RS :
ABDOMEN :
LABORATORY DATA :
PRELIMINARY INVESTIGATIONS :
TEST RESULT
Blood Sugar
Blood Urea, Serum Creatinine
CBC
Serum Bilirubin
Direct / indirect bilirubin
AST/ALT
SAP
Total protein
Serum albumin / globulin
CXR PA View
ECG
USG Abdomen / CT
Sputum AFB
SPECIAL INVESTIGATIONS :
ECHO :
Sputum  C/S :
CT / HRCT CHEST :
Bronchoscopy :
INFERENCE :
MASTER CHART
MASTER CHART- Hemoptysis causes
S.
no Age Sex LFT RFT CXR
Sputum
for AFB
Sputum
C/S
Sputum
for
malignant
cells
ECHO INR CT/HRCTthorax
Broncho
Scopy
Diagnosis
1 50 M N N Ec Ch neg S.Pneu - - - Ec Ch Ec Ch B E
2 30 M N N Infil+ + neg
- - - - -
PT
3 64 M  N N N neg NG - - - - Br Chr Br
4 55 M N N Fb
scar+
neg neg
- - - - -
PT seq
5 53 M N N Infil+ + neg
- - - - -
PT
6 52 M N N Infil+ + neg
- - - - -
PT
7 47 M N N Infil+ + neg
- - - - -
PT
8 26 M N N Infil+ + neg
- - - - -
PT
9 64 M N N Fb
scar+
neg neg
- - - - -
PT seq
10 49 M N N Ca mg
- - -
MS
with
PHT
3.4 - - RHD
11 21 M N N Infil+ + neg
- - - - -
PT
12 50 M N N Con neg Kleb - - - Con - Pneum
13 62 M N N N neg NG - - - - Br Chr br
14 30 M N N Con neg Kleb - - - Con - Pneum
15 42 M N N Infil+ + neg - - - - - PT
16 57 M N N Infil+ + neg - - - - - PT
17 29 M N N Infil+ + neg - - - - - PT
18 56 M N N Ec Ch neg S.Pneu - - - Ec Ch Ec Ch B E
19 48 M N N Infil+ + neg - - - - - PT
20 45 M N N N neg NG - - - - Br Chr Br
21 60 M N N Infil+ + neg - - - - - PT
22 38 M N N Infil+ + neg - - - - - PT
23  54 M N N Infil+ + neg - - - - - PT
24 70 M N N Ho o - - + - - malig GR Ca Br
25 62 M N N Infil+ + neg - - - - - PT
S.
no Age Sex LFT RFT CXR
Sputum
for AFB
Sputum
C/S
Sputum
for
malignant
cells
ECHO INR CT/HRCTthorax
Broncho
Scopy
Diagnosis
26 22 M  N N Ca  mg  - -
-
MS
with
PHT
3.5 - -
RHD
27 50 M N N Fb
scar+
neg neg - - - - - PT seq
28 60 M N N N neg NG - - - - Br Chr Br
29 30 M N N Infil+ + neg - - - - - PT
30 57 M N N Infil+ + Neg
- - - - -
PT
31 70 M N N Infil+ + neg - - - - - PT
32 45 M N N Ec Ch neg S.Pneu - - - Ec Ch Ec Ch B E
33 30 M N N Infil+ + Neg - - - - - PT
34 40 M N N Fb
scar+
neg Neg
- - - - -
PT seq
35 45 M N N Infil+ + neg - - - - - PT
36 60 M N N Infil+ + neg - - - - - PT
37 50 M N N Fb
scar+
neg neg
- - - - -
PT seq
38 47 F N N Infil+ + neg - - - - - PT
39 65 F N N Fb
scar+
neg neg
- - - - -
PT seq
40 45 F N N Infil+ + neg - - - - - PT
41 56 F N N N neg NG - - - - Br Chr Br
42 47 F N N Fb
scar+
neg neg
- - - - -
PT seq
43 23 F N N Infil+ + neg - - - - - PT
44 45 F N N Fb
scar+
neg neg
- - - - -
PT seq
45 35 F N N LA neg Kleb - - - LA - L A
46 40 F N N Infil+ + neg - - - - - PT
47 45 F N N Ca  mg  - -
-
MS
with
PHT
3.9 - - RHD
48 39 F N N Infil+ + neg - - - - - PT
49 55 F N N N neg NG - - - - Br Chr br
50 42 F N N Infil+ + neg - - - - - PT
51 70 F N N Infil+ + neg - - - - - PT
S.
no Age Sex LFT RFT CXR
Sputum
for AFB
Sputum
C/S
Sputum
for
malignant
cells
ECHO INR CT/HRCTthorax
Broncho
Scopy
Diagnosis
52 14 F N N Ho o - - + - - malig GR Ca Br
53 45 F N N Ho o - - + - - malig GR Ca Br
54 48 F N N Infil+ + neg - - - - - PT
55  57 F N N Fb
scar+
neg neg
- - - - -
PT seq
56 27 F N N Infil+ + neg - - - - - PT
57 45 F N N Infil+ + neg - - - - - PT
58 28 F N N Infil+ + neg - - - - - PT
59 60 F N N Cavity
with
crescent
sign
neg neg
- - -
Cavity
with
crescent
sign
-
Asper
60 60 F N N Fb
scar+
neg neg
- - - - -
PT seq
61 42 F N N Infil+ + neg - - - - - PT
62 40 F N N Infil+ + neg - - - - - PT
63 63 F N N Fb
scar+
neg neg
- - - - -
PT seq
64 75 F N N Ec Ch neg S.Pneu - - - Ec Ch Ec Ch B E
65 40 F N N Infil+ + neg - - - - - PT
66 50 F N N Infil+ + neg - - - - - PT
67 45 F N N Fb
scar+
neg neg
- - - - -
PT seq
68 43 F N N Infil+ + neg - - - - - PT
69 27 F N N Infil+ + neg - - - - - PT
70 65 F N N Fb
scar+
neg neg
- - - - -
PT seq
71 42 F N N Fb
scar+
Neg neg
- - - - -
PT seq
72 24 F N N Ca mg
- - -
MS
with
PHT
3.6 - -
RHD
73 30 F N N Infil+ + Neg - - - - - PT
74 19 F N N Infil+ + Neg - - - - - PT
75 65 F N N Infil+ + Neg - - - - - PT
76 50 F N N Infil+ + neg - - - - - PT
S.
no Age Sex LFT RFT CXR
Sputum
for AFB
Sputum
C/S
Sputum
for
malignant
cells
ECHO INR CT/HRCTthorax
Broncho
Scopy
Diagnosis
77 27 F N N Infil+ + neg - - - - - PT
78 50 F N N Fb
scar+
neg neg
- - - - -
PT seq
79 53 F N N Infil+ + Neg - - - - - PT
80 52 F N N Fb
scar+
neg Neg
- - - - -
PT seq
81 25 F N N Infil+ + neg - - - - - PT
82 60 F N N Infil+ + neg - - - - - PT
83 50 F N N Fb
scar+
neg neg
- - - - -
PT seq
84 70 F N N Ec Ch neg S.Pneu - - - Ec Ch Ec Ch B E
85 21 F N N Infil+ + neg - - - - - PT
86 67 F N N Ho o - - + - - malig GR Ca br
87 45 F N N Infil+ + neg - - - - - PT
88 61 M  N N Fb
scar+
Neg neg
- - - - -
PT seq
89 35 M  N N Infil+ + neg - - - - - PT
90 47 M  N N Ec Ch Neg Kleb - - - Ec Ch Ec Ch B E
91 52 M N N N Neg NG - - - - Br Chr Br
92 37 M N N Infil+ + neg - - - - - PT
93 50 M N N Fb
scar+
Neg neg
- - - - -
PT seq
94 62 M N N Ho o - - + - - malig GR Ca br
95 30 M N N Infil+ + neg - - - - - PT
96 63 M N N Fb
scar+
neg neg
- - - - -
PT seq
97 42 M N N Infil+ + neg - - - - - PT
98 32 M N N Infil+ + neg
- - - - -
PT
99 48 M N N LA neg Kleb - - - LA - L A
100 30 M N N Fb
scar+
neg neg
- - - - -
PT seq
Bronchial Artery Embolisation( BAE) – Follow up study
(6 months)
S No Age Sex
BAE
procedure
Post
procedural
hemoptysis
RFT CT thorax
1 65 M N A N R UL cavity
2 50 F N Present N R UL cavity
3 57 F N A N R UL cavity
4 45 M N A N Non cavitatory
5 45 F N A N Non cavitatory
6 50 M N Present N R UL cavity
7 33 M Failure A N Non cavitatory
8 28 M N Present N Non cavitatory
9 43 M N A N R UL cavity
10 32 M N A N L UL cavity
11 50 M N A N L UL cavity
12 29 M N A N R UL, ML cavity
13 16 M N A N L UL cavity
14 40 M N A N Non cavitatory
15 28 F N A N Non cavitatory
16 43 M N Present N Non cavitatory
17 37 M N A N Non cavitatory
18 29 M N A N R UL cavity
19 27 F N A N R UL cavity
20 22 M N Present N L UL cavity
A    -    Absent N -   Normal
ABBREVIATION
Infil+                      -  Infiltrates
Fb scar+                 -  Fibrotic scar
LA                          -  Lung Abscess
Con                        -  Consolidation
Ho o                       -  Homogenous opacity
Ec ch                      -  Ectatic changes
Ca mg                     -  Cardiomegaly
Neg                         -  Negative
Kleb                        -  Klebsiella
S. Pne                     -  Streptococcus pneumoniae
NG                          -  No Growth
Malig                       -  Malignancy
N                            -   Normal
Br                           -  Bronchitis
GR                         -  Growth
PT                          -  Pulmonary tuberculosis
RHD                       -  Rheumatic heart disease
Chr Br                      -  Chronic bronchitis
Ca Br                      -   Carcinoma Bronchus
PT seq                    -    Pulmonary Tuberculosis sequelae
B E                         -    Bronchiectasis
Pneum                    -    Pneumonia
LA                         -    Lung abscess
Asper                     -    Aspergilloma
R -  Right
L - Left
UL -  Upper Lobe
ML -Middle Lobe
LL - Lower Lobe

